A Phase I, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of RO7020531: (1). Single and Multiple Ascending Doses in Healthy Male and Female Subjects; (2). 6-Week Treatment of Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs RO 7020531 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 20 Nov 2017 Planned number of patients changed from 110 to 140.
- 05 Oct 2017 Planned End Date changed from 19 Apr 2019 to 24 Apr 2019.
- 05 Oct 2017 Planned primary completion date changed from 19 Apr 2019 to 24 Apr 2019.